517920-75-1

Usage

Uses

3-Chloro-2-fluorophenylhydrazine, HCl

InChI:InChI=1/C6H6ClFN2.ClH/c7-4-2-1-3-5(10-9)6(4)8;/h1-3,10H,9H2;1H

Upstream product

• 650578-82-8 3-chloro-2-fluoroaniline hydrochloride 

Downstream Products

• 1357191-83-3 3-[1-(3-chloro-2-fluorophenyl)-1H-pyrazol-5-yl]-1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxypyridazin-4(1H)-one 
• 1422386-21-7 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1422386-19-3 1-(3-chloro-2-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 
• 1422385-89-4 ethyl 5-amino-1-(3-chloro-2-fluorophenyl)-1H-pyrazole-4-carboxylate 
• 1422386-76-2 (E)-1-benzylidene-2-(3-chloro-2-fluorophenyl)hydrazine 
• 1422386-49-9 N'-(3-chloro-2-fluorophenyl)acetohydrazide 
• 926634-47-1 4-(6-chloro-7-fluoro-1H-indol-2-yl)-benzoic acid methyl ester 

Relevant academic research and scientific papers

Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists

The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I